Replies to post #226326 on Biotech Values

[DewDiligence]

…the ability to lower HBsAg (albeit modestly) w data to date is still much better than you could ever get with a nuke.

I consider lowered HBsAg a biomarker, rather than a curative force in its own right.

I’m generally bearish on RNAi approaches to HBV because I doubt that they’ll be able to eradicate cccDNA and achieve a cure from a short course of therapy. If they can’t do that, a regimen of small-molecule (oral) drugs would seem to be more attractive commercially.